{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9"],"submitter":["Chen W"],"pubmed_abstract":["Objectives
Evidence from systematic reviews/meta-analyses about the efficacy and safety of Qishen Yiqi (QSYQ) dripping pills in chronic heart failure (CHF) remains unclear. This study comprehensively reviewed available systematic reviews on latest evidence to provide reliable information for the clinical use of QSYQ in CHF.Methods
The systematic review was performed on studies retrieved from six major medical databases. Eligible studies were evaluated in terms of methodological quality and quality of evidence using the Assessment of Multiple Systematic review 2 (AMSTAR-2) tool, the Risk of Bias in Systematic Reviews (ROBIS) was used to assess the risk of bias, and the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) 2020 was utilized for assessing "],"journal":["Frontiers in cardiovascular medicine"],"pagination":["1001072"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9637556"],"repository":["biostudies-literature"],"pubmed_title":["The role of Qishen Yiqi dripping pills in treating chronic heart failure: An overview of systematic reviews and meta-analyses."],"pmcid":["PMC9637556"],"pubmed_authors":["Liu Y","Yan J","Chen J","Wang D","Chen W","Wang Y","Yan X"],"additional_accession":[]},"is_claimable":false,"name":"The role of Qishen Yiqi dripping pills in treating chronic heart failure: An overview of systematic reviews and meta-analyses.","description":"Objectives
Evidence from systematic reviews/meta-analyses about the efficacy and safety of Qishen Yiqi (QSYQ) dripping pills in chronic heart failure (CHF) remains unclear. This study comprehensively reviewed available systematic reviews on latest evidence to provide reliable information for the clinical use of QSYQ in CHF.Methods
The systematic review was performed on studies retrieved from six major medical databases. Eligible studies were evaluated in terms of methodological quality and quality of evidence using the Assessment of Multiple Systematic review 2 (AMSTAR-2) tool, the Risk of Bias in Systematic Reviews (ROBIS) was used to assess the risk of bias, and the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) 2020 was utilized for assessing ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-19T23:14:17.27Z","creation":"2025-02-19T00:31:43.912Z"},"accession":"S-EPMC9637556","cross_references":{"pubmed":["36352851"],"doi":["10.3389/fcvm.2022.1001072"]}}